You are here:Home-Research Areas-Neurological Disease-Parkinson Disease

Request The Product List ofParkinson Disease Parkinson Disease

Cat. No. Product Name CAS No. Information
PC-35791

Nebicapone

274925-86-9

Nebicapone (BIA 3-202, BIA3-202) is a potent, long-acting, reversible and competitive peripheral inhibitor of catechol-O-methyltransferase (COMT) with IC50 of 3.7 nM for rat brain COMT, much less potent for liver COMT with IC50 of 696 nM; enhances the availability of L-DOPA to the brain and reduces its O-methylation, Nebicapone (BIA 3-202, BIA3-202) is an adjunct to levodopa/carbidopa or levodopa/benserazide in the treatment of Parkinson's disease.

Parkinson Disease

Phase 1 Discontinued

PC-61600

AQW-051

669770-29-0

AQW-051 is a novel, potent and selective, orally bioavailable, brain-penetrant α7 nAChR partial agonist with pKd of 7.56; displays high selectivity (>100-fold) over other nACh receptors; stimulates calcium influx in GH3–ha7-22 cells recombinantly expressing the human α7-nACh receptor with pEC50 of 7.41; facilitates learning/memory performance in mice; reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.

Parkinson Disease

Phase 2 Clinical

PC-70174

CEP-1347

156177-65-0

CEP-1347 (KT-7515) is a potent and selective MLK inhibitor that completely rescues motoneurons and inhibits JNK1 activation with IC50 of 20 nM; has weak inhibitory activity for Trk A and MLCK; promotes motoneuron survival and simultaneously inhibits the JNK1 signaling cascade; inhibits recombinant MLK1/2/3 with IC50 of 23-51 nM; blocks cell death (overexpression of MLK3) in CHO cells; elicits neuroprotective and anti-inflammatory responses in models of neurodegenerative diseases.

Parkinson Disease

Phase 2 Discontinued

PC-45425

GNE-7915 tosylate

2070015-00-6

GNE-7915 tosylate (GNE7915 tosylate) is a highly potent, selective, and brain-penetrable LRRK2 inhibitor with IC50 of 1.9 nM; shows 1/187 kinases with 50% inhibition at 0.1 uM; possesses an ideal balance of LRRK2 cellular potency, broad kinase selectivity, metabolic stability, and brain penetration across multiple species.

Parkinson's Disease

Preclinical

PC-45424

GNE-7915

1351761-44-8

A highly potent, selective, and brain-penetrant LRRK2 inhibitor with IC50 of 1.9 nM; shows 1/187 kinases with 50% inhibition at 0.1 uM; possesses an ideal balance of LRRK2 cellular potency, broad kinase selectivity, metabolic stability, and brain penetration across multiple species.

Parkinson's Disease

Preclinical

PC-35982

SUVN-G3031

1394808-82-2 SUVN-G3031 (SUVN-G 3031) is a potent, selective, orally active histamine H3 receptor (H3R) inverse agonist with Ki of 8.73 nM (hH3R); exhibited an IC50 of 20 nM with progressive inhibition of (R)-α-methylhistamine (0.03 µM) induced agonist activity in [35S]-GTPγS binding assay using CHO-K1 cells expressing human H3R membranes; reverses (R)-α-methylhistamine induced dipsogenia in vivo.

Parkinson Disease

Phase 1 Clinical

PC-35981

SUVN-G3031 dihydrochloride

1394808-20-8 SUVN-G3031 (SUVN-G 3031) is a potent, selective, orally active histamine H3 receptor (H3R) inverse agonist with Ki of 8.73 nM (hH3R); exhibited an IC50 of 20 nM with progressive inhibition of (R)-α-methylhistamine (0.03 µM) induced agonist activity in [35S]-GTPγS binding assay using CHO-K1 cells expressing human H3R membranes; reverses (R)-α-methylhistamine induced dipsogenia in vivo.

Parkinson Disease

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com